Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because:
Given that some pharmaceutical and medical device companies have interpreted the regulations to require AE reporting of their research and analytics providers, a marketing research and data analytics company that accepts this responsibility for reporting AEs should, at a minimum, obtain contractual terms that:
Such contract terms extend some measure of legal protection to marketing research and data analytics companies and help to safeguard the ethical integrity of the research process, but they do not overcome the Insights Association’s overriding concerns about the potential risks of requiring routine pharmaceutical marketing research and data analytics studies to serve as a direct instrument of the “pharmacovigilence” process.
The market research and data analytics industry is best-equipped to advance pharmacovigilence by encouraging voluntary reporting by physicians and patients. Recognizing that the industry’s extensive contact with patients and physicians puts us in a unique position to encourage and facilitate AE reporting by those who experience them and the medical professionals who observe them, the Insights Association recommends that research and analytics companies play an indirect role, by reminding respondents of the importance of AE reporting and providing them with information to help them do so.
This information is not intended and should not be construed as or substituted for legal advice. It is provided for informational purposes only. It is advisable to consult with your attorney on the precise scope and interpretation of any laws/regulation/legislation and their impact on your particular business.
The insights industry faced more than just April showers, as the first full month of spring brought ...
Some insights professionals and clients are wondering, with the federal government directives agains...
A proposal from the Consumer Financial Protection Bureau (CFPB) could unfairly apply restrictions in...
In comments to the House Energy & Commerce Committee, the Insights Association (IA) recommended “a ...
Utah Governor Spencer Cox (R) signed H.B. 418 into law on March 27, 2025, adding a correction right ...
March blew in like a lion for the insights industry, but it shows no signs of leaving like a lamb, a...
0 Comments